Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective Study With Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN (Squamous Cell Carcinoma of the Head and Neck): Real World Data.

NCT04672772 is registered in ClinicalTrials.gov with Grupo Español de Tratamiento de Tumores de Cabeza y Cuello as lead sponsor.

NCT NCT04672772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04672772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective Study With Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN (Squamous Cell Carcinoma of the Head and Neck): Real World Data.
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase
Observational
Overall status
Completed
Start date
December 18, 2020
Completion date
January 17, 2022
Enrollment
531 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck